1. Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs
- Author
-
Alberto Massarotti, Tracey Pirali, Silvio Aprile, Clarissa Landoni, Roger L. Williams, Valentina Mercalli, Alessia Griglio, Rangel L. Silva, Carlo Cosimo Campa, Jean Piero Margaria, Alex Berndt, Elisa Ciraolo, Emilio Hirsch, Marta Serafini, Giovanni Sorba, Giorgio Grosa, and Gian Cesare Tron
- Subjects
0301 basic medicine ,Carboxylic Acids ,Quinolones ,Pharmacology ,click chemistry ,inflammation ,nitrogen heterocycles ,phosphoinositide 3-kinases ,prodrugs ,Biochemistry ,Mice ,Phosphatidylinositol 3-Kinases ,Drug Discovery ,Protein Isoforms ,Enzyme Inhibitors ,General Pharmacology, Toxicology and Pharmaceutics ,Phosphoinositide-3 Kinase Inhibitors ,chemistry.chemical_classification ,Full Paper ,biology ,Full Papers ,Prodrug ,Toxicity ,Molecular Medicine ,medicine.symptom ,Protein Binding ,Gene isoform ,Carboxylic acid ,Inflammation ,Molecular Dynamics Simulation ,Inhibitory Concentration 50 ,Structure-Activity Relationship ,03 medical and health sciences ,Cell Line, Tumor ,Microsomes ,medicine ,Animals ,Humans ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,Binding Sites ,Phosphoinositide 3-kinase ,Organic Chemistry ,Hydrogen Bonding ,030104 developmental biology ,Systemic toxicity ,chemistry ,Drug Design ,biology.protein - Abstract
Activation of the phosphoinositide 3‐kinase (PI3K) pathway is a key signaling event in cancer, inflammation, and other proliferative diseases. PI3K inhibitors are already approved for some specific clinical indications, but their systemic on‐target toxicity limits their larger use. In particular, whereas toxicity is tolerable in acute treatment of life‐threatening diseases, this is less acceptable in chronic conditions. In the past, the strategy to overcome this drawback was to block selected isoforms mainly expressed in leukocytes, but redundancy within the PI3K family members challenges the effectiveness of this approach. On the other hand, decreasing exposure to selected target cells represents a so‐far unexplored alternative to circumvent systemic toxicity. In this manuscript, we describe the generation of a library of triazolylquinolones and the development of the first prodrug pan‐PI3K inhibitor.
- Published
- 2017
- Full Text
- View/download PDF